Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other financing activities (2018)

Denali Therapeutics (DNLI) has disclosed Other financing activities for 1 consecutive years, with -$1.3 million as the latest value for Q4 2018.

  • Quarterly Other financing activities changed N/A to -$1.3 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Sep 2019, down 196.72% year-over-year, with the annual reading at $324000.0 for FY2025, N/A changed from the prior year.
  • Other financing activities for Q4 2018 was -$1.3 million at Denali Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Other financing activities was $1.3 million in Q3 2018, with the low at -$1.3 million in Q4 2018.